Pharmaceutical group Ascendis Health has released its twice delayed annual results with a reported normalised loss after tax of R459 million. The company is also looking to sell off non-core assets after its share price has come under severe pressure this year which they have attributed to impairment costs of R4.2 billion. Ascendis Health CEO, Mark Sardi joins CNBC Africa for more.